The estimated Net Worth of Roy A Whitfield is at least 10.5 百万$ dollars as of 14 June 2023. Mr. Whitfield owns over 30,000 units of Nektar Therapeutics stock worth over 270,313$ and over the last 21 years he sold NKTR stock worth over 9,806,535$. In addition, he makes 384,228$ as Lead Independent Director at Nektar Therapeutics.
Roy has made over 57 trades of the Nektar Therapeutics stock since 2005, according to the Form 4 filled with the SEC. Most recently he sold 30,000 units of NKTR stock worth 17,100$ on 14 June 2023.
The largest trade he's ever made was selling 50,000 units of Nektar Therapeutics stock on 18 November 2013 worth over 2,368,500$. On average, Roy trades about 8,660 units every 60 days since 2003. As of 14 June 2023 he still owns at least 216,250 units of Nektar Therapeutics stock.
You can see the complete history of Mr. Whitfield stock trades at the bottom of the page.
Roy A. Whitfield serves as Lead Independent Director of the Company. Mr. Whitfield is the former Chairman of the Board and Chief Executive Officer of Incyte Corporation (“Incyte”), a drug discovery and development company he co-founded in 1991. From January 1993 to November 2001, Mr. Whitfield served as its Chief Executive Officer and from November 2001 until June 2003 as its Chairman. He also served as a director of Incyte from 1991 to January 2014. From 1984 to 1989, Mr. Whitfield held senior operating and business development positions with Technicon Instruments Corporation (“Technicon”), a medical instrumentation company, and its predecessor company, Cooper Biomedical, Inc., a biotechnology and medical diagnostics company. Prior to his work at Technicon, Mr. Whitfield spent seven years with the Boston Consulting Group’s international consulting practice. He currently serves as a director of Station X, Inc. a private company. Mr. Whitfield previously served as the Executive Chairman of the board of directors of Bioseek and as member of the board of directors of Illumina, Inc. Mr. Whitfield received a B.S. in mathematics from Oxford University and an M.B.A. from Stanford University.
As the Lead Independent Director of Nektar Therapeutics, the total compensation of Roy Whitfield at Nektar Therapeutics is 384,228$. There are 12 executives at Nektar Therapeutics getting paid more, with Jonathan Zalevsky having the highest compensation of 39,242,200$.
Roy Whitfield is 66, he's been the Lead Independent Director of Nektar Therapeutics since 2019. There are 4 older and 14 younger executives at Nektar Therapeutics. The oldest executive at Nektar Therapeutics is Dr. Brian L. Kotzin, 72, who is the Sr. VP of Clinical Devel. & Head of Immunology.
Roy's mailing address filed with the SEC is C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158.
Over the last 21 years, insiders at Nektar Therapeutics have traded over 57,608,493$ worth of Nektar Therapeutics stock and bought 90,000 units worth 1,628,550$ . The most active insiders traders include Howard W Robin、Gil M Labrucherie、John Nicholson. On average, Nektar Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of 36,648$. The most recent stock trade was executed by Jonathan Zalevsky on 19 August 2024, trading 6,866 units of NKTR stock currently worth 8,788$.
nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
Nektar Therapeutics executives and other stock owners filed with the SEC include: